RCM-1 Xenograft Model Service for Colon Cancer

The RCM-1 xenograft model offers a robust preclinical platform for evaluating therapeutic candidates against colorectal carcinoma, leveraging a well-characterized human rectal adenocarcinoma cell line with distinct molecular and growth properties. Alfa Cytology delivers comprehensive, customized RCM-1 xenograft services---from model construction and in-life monitoring to endpoint analysis---supporting your colon cancer drug discovery and development programs with reliable, reproducible data.

Overview of RCM-1 Xenograft Model for Colon Cancer

The RCM-1 cell line was established from a well-differentiated rectal adenocarcinoma resected from a 73-year-old female patient. It exhibits epithelial morphology with adherent growth characteristics and is classified under the CMS2 consensus molecular subtype, associated with canonical WNT and MYC signaling activation. RCM-1 cells demonstrate a relatively slow proliferation rate in vitro, with a doubling time of approximately 60-71 hours, and form well-differentiated adenocarcinoma xenografts in immunodeficient mice with tumor volumes reaching 100 mm^3 typically within 30-40 days post-inoculation. The cell line secretes carcinoembryonic antigen (CEA) and proteinase inhibitors, and has been validated for drug sensitivity profiling against standard chemotherapeutics including oxaliplatin and 5-fluorouracil, making it a valuable tool for preclinical pharmacology studies.

In xenograft applications, RCM-1 tumors maintain histological features consistent with the primary tumor, including glandular architecture and mucin production, providing a physiologically relevant model for evaluating anti-tumor efficacy, pharmacokinetics, and biomarker dynamics. The model has been employed in studies investigating FOXM1 inhibition, Wnt/beta-catenin pathway modulation, and differentiation-inducing agents, demonstrating its utility across diverse therapeutic modalities. Subcutaneous implantation remains the most common route, though orthotopic approaches can be adapted for studies requiring organ-specific microenvironment interactions.

Figure 1. RCM-1 inhibits cancer cell proliferation and increases the mitotic and cell cycle duration in vitro. (Shukla, S, et al., 2019)

Cell Line Information: RCM-1

The following table summarizes the key characteristics of the RCM-1 cell line, derived from authenticated sources including the Japanese Collection of Research Bioresources (JCRB) and the Colorectal Cancer Atlas database.

Our Services

Alfa Cytology provides end-to-end RCM-1 xenograft model services tailored to your preclinical research objectives. Our experienced team manages every phase of the study---from cell line authentication and mouse husbandry to tumor monitoring, blood/tissue collection, and histopathological analysis---ensuring high-quality, reproducible data that advances your colon cancer therapeutic pipeline. Whether you require standard subcutaneous models or customized orthotopic implantation with advanced imaging endpoints, we deliver flexible, GLP-compliant solutions designed to meet your project timelines and regulatory requirements.

Workflow of RCM-1 Xenograft Model Construction

The construction of the RCM-1 xenograft model follows a standardized, quality-controlled workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. Each step is executed under SPF conditions with rigorous documentation and quality checks.

1. Cell Line Preparation and Authentication: RCM-1 cells are expanded in vitro under standardized culture conditions (RPMI 1640/Ham's F-12, 10% FBS, 37 degrees C, 5% CO2). Prior to inoculation, cells undergo STR authentication, mycoplasma testing, and viability assessment (typically >95% viable by trypan blue exclusion).
2. Animal Selection and Acclimatization: Immunodeficient mice (commonly BALB/c nude or NOD-SCID) are selected based on study design and housed under SPF conditions for a minimum 7-day acclimatization period. Health status is verified before tumor cell inoculation.
3. Tumor Cell Inoculation: A suspension of 1-5 x 10^6 RCM-1 cells in 100-200 microL serum-free medium (often Matrigel-supplemented for enhanced engraftment) is injected subcutaneously into the flank or orthotopically into the cecal wall, depending on the study objective.
4. Tumor Monitoring and Measurement: Tumor growth is monitored twice weekly using digital calipers. Tumor volume is calculated via the modified ellipsoid formula (V = 0.5 x L x W^2). Mice are randomized into treatment groups once tumors reach 100-150 mm^3.
5. Treatment Administration and In-Life Observations: Test compounds are administered according to the study protocol (IV, IP, PO, or SC routes). Body weight, clinical signs, and tumor dimensions are recorded throughout the treatment period to assess efficacy and toxicity.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), biomarker analysis, and pharmacokinetic profiling. Blood samples are collected for hematology and clinical chemistry assessments.
7. Data Analysis and Reporting: Tumor growth inhibition (TGI), tumor regression rates, and survival curves are calculated. All data are compiled into a comprehensive study report with statistical analysis, raw data tables, and representative images.

Figure 2: Schematic workflow illustrating the derivation and construction of the RCM-1 Xenograft Model at Alfa Cytology.

Case Study-RCM-1 Xenograft Model Development

Alfa Cytology has successfully established and validated the RCM-1 xenograft model for multiple client programs targeting colorectal carcinoma. In a representative study, RCM-1 cells were inoculated subcutaneously into immunodeficient mice, achieving consistent tumor engraftment with predictable growth kinetics. Treatment arms evaluated a panel of candidate therapeutics, including standard-of-care agents and novel targeted compounds, with tumor growth inhibition and biomarker modulation assessed as primary endpoints. Detailed efficacy data, pharmacokinetic profiles, and histopathological findings are available upon request under confidentiality agreements. Contact our team to discuss how the RCM-1 model can be configured for your specific research objectives.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise, operational excellence, and client-focused flexibility to deliver preclinical tumor model services that accelerate your drug development timeline. Our RCM-1 xenograft service is built on rigorous quality standards and tailored execution.

• Authenticated cell lines with verified STR profiles and documented passage history ensure model integrity and reproducibility.
• Customizable study designs including subcutaneous, orthotopic, and metastasis models with flexible dosing schedules and endpoint panels.
• Real-time tumor monitoring using digital calipers and optional non-invasive imaging (bioluminescence, MRI) for longitudinal data collection.
• Comprehensive endpoint analysis encompassing histopathology, immunohistochemistry, biomarker quantification, and PK/PD correlation.
• Dedicated project management with transparent reporting, milestone tracking, and rapid turnaround to meet aggressive development timelines.
• Competitive pricing with no hidden costs, supported by detailed proposals and clear study protocols from project initiation.

Contact Us

Ready to advance your colorectal cancer preclinical program? Contact us today to discuss your RCM-1 xenograft model requirements, request a customized study proposal, or schedule a consultation with our scientific team. Reach out to us via email or through our inquiry form, and let Alfa Cytology be your trusted partner in translating promising therapeutics from bench to bedside.

For research use only. Not intended for any clinical use.